Alzheimer's Disease and Mild Cognitive Impairment

Neurologic Clinics

Volumn 25, Issue 3, 2007, Pages 577-609

  Kelley, Brendan J ^a   Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; DONEPEZIL; DULOXETINE; FLUOXETINE; GALANTAMINE; HALOPERIDOL; LORAZEPAM; MEMANTINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; OXAZEPAM; PAROXETINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TACRINE; TEMAZEPAM; TRAZODONE; VALPROATE SEMISODIUM; VENLAFAXINE; ZOLPIDEM TARTRATE;

AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY DISORDER; APATHY; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DELUSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG MECHANISM; HALLUCINATION; HEADACHE; HORMONE SUBSTITUTION; HUMAN; INSOMNIA; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEIZURE; SIDE EFFECT; VIVID DREAM; VOMITING; WEIGHT REDUCTION;

AGED; ALZHEIMER DISEASE; COGNITION DISORDERS; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 34447303785     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2007.03.008     Document Type: Review

References (200)

1. Brookmeyer R., Gray S., and Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88 9 (1998) 1337-1342
2. Petersen R.C. Aging, mild cognitive impairment, and Alzheimer's disease. Neurol Clin 18 4 (2000) 789-805
3. Petersen R.C. Mild cognitive impairment: transtion from aging to Alzheimer's disease. In: Iqbal K., Sisodia S.S., and Winblad B. (Eds). Alzheimer's disease: advances in etiology, pathogenesis and therapeutics (2001), J Wiley & Sons, Ltd., West Sussex (England) 141-151
4. Knopman D.S., DeKosky S.T., Cummings J.L., et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 9 (2001) 1143-1153
5. Petersen R.C., Stevens J.C., Ganguli M., et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 9 (2001) 1133-1142
6. Doody R.S., Stevens J.C., Beck C., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 9 (2001) 1154-1166
7. Ivnik R.J., Smith G.E., Lucas J.A., et al. Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance. Neuropsychology 13 1 (1999) 121-127
8. Petersen R.C. Mild cognitive impairment: aging to Alzheimer's disease (2003), Oxford University Press, Oxford (UK)
9. Siwinski M., Lipton R.B., Buschke H., et al. The effects of preclinical dementia on estimates of normal cognitive functioning in aging. J Gerontol B Psychol Sci Soc Sci 51 4 (1996) P217-P225
10. Backman L., Jones S., Berger A.K., et al. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 19 4 (2005) 520-531
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd edition, revised (1987), American Psychiatric Association, Washington, DC
12. Fleming K.C., Adams A.C., and Petersen R.C. Dementia: diagnosis and evaluation. Mayo Clin Proc 70 11 (1995) 1093-1107
13. Burns A., Jacoby R., and Levy R. Psychiatric phenomena in Alzheimer's disease. IV: disorders of behaviour. Br J Psychiatry 157 (1990) 86-94
14. Drevets W.C., and Rubin E.H. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 25 1 (1989) 39-48
15. Rosen J., and Zubenko G.S. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry 29 3 (1991) 224-232
16. Teri L., Larson E.B., and Reifler B.V. Behavioral disturbance in dementia of the Alzheimer's type. J Am Geriatr Soc 36 1 (1988) 1-6
17. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Diagnosis of Alzheimer's Disease. Consensus recommendations for the postmortem Diagnosis of Alzheimer's disease. Neurobiol Aging 18 4 Suppl (1997) S1-S2
18. Kukull W.A., and Ganguli M. Epidemiology of dementia: concepts and overview. Neurol Clin 18 4 (2000) 923-950
19. Bachman D.L., Wolf P.A., Linn R., et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 42 1 (1992) 115-119
20. Canadian Study of Health and Aging Working Group. Study methods and prevalence of dementia. CMAJ 150 6 (1994) 899-913
21. Evans D.A., Funkenstein H.H., Albert M.S., et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262 18 (1989) 2551-2556
22. Hendrie H.C., Osuntokun B.O., Hall K.S., et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry 152 10 (1995) 1485-1492
23. Hofman A., Ott A., Breteler M.M., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349 9046 (1997) 151-154
24. Kokmen E., Beard C.M., Offord K.P., et al. Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975. Neurology 39 6 (1989) 773-776
25. White L., Petrovitch H., Ross G.W., et al. Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. JAMA 276 12 (1996) 955-960
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition text revision (DSM-IV-TR) (2000), American Psychiatric Association, Washington, DC
27. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 7 (1984) 939-944
28. Folstein M., Folstein S., and McHugh P. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
29. Teng E.L., and Chui H.C. The modified mini-mental state (3MS) examination. J Clin Psychiatry 48 8 (1987) 314-318
30. Katzman R., Brown T., Fuld P., et al. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 140 6 (1983) 734-739
31. Kokmen E., Smith G.E., Petersen R.C., et al. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol 48 7 (1991) 725-728
32. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 11 (1993) 2412-2414
33. Jack Jr. C.R., Petersen R.C., Xu Y.C., et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 49 3 (1997) 786-794
34. Jack Jr. C.R., Petersen R.C., Xu Y.C., et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52 7 (1999) 1397-1403
35. Killiany R.J., Gomez-Isla T., Moss M., et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 47 4 (2000) 430-439
36. Xu Y., Jack Jr. C.R., O'Brien P.C., et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 54 9 (2000) 1760-1767
37. Wahlund L.O., Almkvist O., Blennow K., et al. Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup. Top Magn Reson Imaging 16 6 (2005) 427-437
38. Ramani A., Jensen J.H., and Helpern J.A. Quantitative MR imaging in Alzheimer disease. Radiology 241 1 (2006) 26-44
39. Van Gool W.A., Walstra G.J., Teunisse S., et al. Diagnosing Alzheimer's disease in elderly, mildly demented patients: the impact of routine single photon emission computed tomography. J Neurol 242 6 (1995) 401-405
40. Claus J.J., van Harskamp F., Breteler M.M., et al. The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease: a population-based study. Neurology 44 3 Pt 1 (1994) 454-461
41. Johnson K.A., Kijewski M.F., Becker J.A., et al. Quantitative brain SPECT in Alzheimer's disease and normal aging. J Nucl Med 34 11 (1993) 2044-2048
42. Johnson K.A., Holman B.L., Rosen T.J., et al. Iofetamine I 123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer's disease. Arch Intern Med 150 4 (1990) 752-756
43. Bartenstein P., Minoshima S., Hirsch C., et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J Nucl Med 38 7 (1997) 1095-1101
44. Mielke R., and Heiss W.D. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. J Neural Transm Suppl 53 (1998) 237-250
45. Silverman D.H., Small G.W., Chang C.Y., et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286 17 (2001) 2120-2127
46. Kantarci K., Jack Jr. C.R., Xu Y.C., et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 55 2 (2000) 210-217
47. Kantarci K., Petersen R.C., Boeve B.F., et al. 1H MR spectroscopy in common dementias. Neurology 63 8 (2004) 1393-1398
48. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55 3 (2004) 306-319
49. Shoghi-Jadid K., Small G.W., Agdeppa E.D., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10 1 (2002) 24-35
50. Small G.W., Kepe V., Ercoli L.M., et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355 25 (2006) 2652-2663
51. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 3 9 (2004) 519-527
52. Johnson K.A. Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B. Curr Neurol Neurosci Rep 6 6 (2006) 496-503
53. Becker P.M., Feussner J.R., Mulrow C.D., et al. The role of lumbar puncture in the evaluation of dementia: the Durham Veterans Administration/Duke University Study. J Am Geriatr Soc 33 6 (1985) 392-396
54. Hardy J., and Gwinn-Hardy K. Genetic classification of primary neurodegenerative disease. Science 282 5391 (1998) 1075-1079
55. Roses A.D., et al. Apolipoprotein E and Alzheimer's disease. In: Rosenberg R.N., Prusiner S.B., and DiMaur O.S. (Eds). The molecular and genetic basis of neurological disease. 2nd edition (1997), Butterworth-Heinemann, Boston 1019-1036
56. Farrer L.A., Cupples L.A., Haines J.L., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278 16 (1997) 1349-1356
57. Mayeux R., Saunders A.M., Shea S., et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's disease centers consortium on apolipoprotein E and Alzheimer's disease. N Engl J Med 338 8 (1998) 506-511
58. Roses A.D., et al. The predictive value of APOE genotyping in the early diagnosis of dementia of the Alzheimer type: data from three independent series. In: Iqbal K., Winblad B., and Nishimura T. (Eds). Alzheimer's disease: biology, diagnosis and therapeutics (1997), John Wiley & Sons, West Sussex (England) 85-91
59. Andreasen N., Hesse C., Davidsson P., et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56 6 (1999) 673-680
60. Galasko D., Chang L., Motter R., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55 7 (1998) 937-945
61. Hulstaert F., Blennow K., Ivanoiu A., et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52 8 (1999) 1555-1562
62. Shoji M., Matsubara E., Kanai M., et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 158 2 (1998) 134-140
63. Stefani A., Martorana A., Bernardini S., et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci 251 1-2 (2006) 124-128
64. Stenset V., Johnsen L., Kocot D., et al. Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42. Neurology 67 5 (2006) 830-833
65. Arai H., Higuchi S., and Sasaki H. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Gerontology 43 Suppl 1 (1997) 2-10
66. Galasko D., Clark C., Chang L., et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 48 3 (1997) 632-635
67. Kurz A., Riemenschneider M., Buch K., et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis Assoc Disord 12 4 (1998) 372-377
68. Andreasen N., Minthon L., Clarberg A., et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 53 7 (1999) 1488-1494
69. Buerger K., Ewers M., Pirttila T., et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129 Pt 11 (2006) 3035-3041
70. Clark C.M., Xie S., Chittams J., et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 60 12 (2003) 1696-1702
71. Schoonenboom N.S., Pijnenburg Y.A., Mulder C., et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62 9 (2004) 1580-1584
72. Buerger K., Teipel S.J., Zinkowski R., et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59 4 (2002) 627-629
73. de la Monte S.M., Volicer L., Hauser S.L., et al. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 32 6 (1992) 733-742
74. de la Monte S.M., and Wands J.R. The AD7c-ntp neuronal thread protein biomarker for detecting Alzheimer's disease. Front Biosci 7 (2002) d989-d996
75. Monte S.M., Ghanbari K., Frey W.H., et al. Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest 100 12 (1997) 3093-3104
76. Ghanbari K., and Ghanbari H.A. A sandwich enzyme immunoassay for measuring AD7C-NTP as an Alzheimer's disease marker: AD7C test. J Clin Lab Anal 12 4 (1998) 223-226
77. Geda Y.E., and Petersen R.C. Clinical trials in mild cognitive impairment. In: Gauthier S., and Cummings J.L. (Eds). Alzheimer's disease and related disorders annual 2001 vol 103 (2001), Martin Dunitz, London 69-83
78. Petersen R.C., Doody R., Kurz A., et al. Current concepts in mild cognitive impairment. Arch Neurol 58 12 (2001) 1985-1992
79. Ritchie K., Artero S., and Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 56 1 (2001) 37-42
80. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56 3 (1999) 303-308
81. Daly E., Zaitchik D., Copeland M., et al. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol 57 5 (2000) 675-680
82. Smith G.E., Petersen R.C., Parisi J.E., et al. Definition, course, and outcome of mild cognitive impairment. Aging Neuropsychology & Cognition 3 2 (1996) 141-147
83. Ivnik R.J., Malec J.F., Smith G.E., et al. Mayo's older Americans normative studies: WAIS-R, WMS-R and AVLT norms for ages 56 to 97. Clin Neuropsychol 6 Suppl (1992) 1-104
84. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Intern Med 256 3 (2004) 183-194
85. Bennett D.A., Wilson R.S., Schneider J.A., et al. Natural history of mild cognitive impairment in older persons. Neurology 59 2 (2002) 198-205
86. Ganguli M., Dodge H.H., Shen C., et al. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 63 1 (2004) 115-121
87. Lopez O.L., Jagust W.J., DeKosky S.T., et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol 60 10 (2003) 1385-1389
88. Knopman D.S., and Ryberg S. A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch Neurol 46 2 (1989) 141-145
89. Petersen R.C. Memory assessment at the bedside. In: Yanagihara T., and Petersen R.C. (Eds). Memory disorders (1991), Dekker, New York 137-152
90. Fox N.C., Warrington E.K., Freeborough P.A., et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 119 Pt 6 (1996) 2001-2007
91. Fox N.C., Crum W.R., Scahill R.I., et al. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 358 9277 (2001) 201-205
92. Schott J.M., Price S.L., Frost C., et al. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology 65 1 (2005) 119-124
93. Small G.W., Mazziotta J.C., Collins M.T., et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273 12 (1995) 942-947
94. Reiman E.M., Caselli R.J., Yun L.S., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334 12 (1996) 752-758
95. Petersen R.C. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 15 3 (2000) 93-101
96. Growdon J.H. Biomarkers of Alzheimer disease. Arch Neurol 56 3 (1999) 281-283
97. Sunderland T., Wolozin B., Galasko D., et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry 46 6 (1999) 750-755
98. Hansson O., Zetterberg H., Buchhave P., et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5 3 (2006) 228-234
99. Petersen R.C., Smith G.E., Ivnik R.J., et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 273 16 (1995) 1274-1278
100. Tierney M.C., Szalai J.P., Snow W.G., et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 46 1 (1996) 149-154
101. Bennett D.A., Schneider J.A., Bienias J.L., et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64 5 (2005) 834-841
102. Petersen R.C., Parisi J.E., Dickson D.W., et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 63 5 (2006) 665-672
103. Riley K.P., Snowdon D.A., and Markesbery W.R. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 51 5 (2002) 567-577
104. Mesulam M., Shaw P., Mash D., et al. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 55 6 (2004) 815-828
105. Grudzien A., Shaw P., Weintraub S., et al. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 28 3 (2007) 327-335
106. Morris J.C., Storandt M., Miller J.P., et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58 3 (2001) 397-405
107. Jicha G.A., Parisi J.E., Dickson D.W., et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63 5 (2006) 674-681
108. Whitehouse P.J., Price D.L., Clark A.W., et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10 2 (1981) 122-126
109. Petersen R.C. Scopolamine induced learning failures in man. Psychopharmacology (Berl) 52 3 (1977) 283-289
110. Bowen D.M., Smith C.B., White P., et al. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99 3 (1976) 459-496
111. Davies P., and Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 8000 (1976) 1403
112. Petersen R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 23 (2005) 2379-2388
113. Rosler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318 7184 (1999) 633-638
114. Tariot P.N., Solomon P.R., Morris J.C., et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54 12 (2000) 2269-2276
115. Feldman H., Gauthier S., Hecker J., et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 63 4 (2004) 644-650
116. Courtney C., Farrell D., Gray R., et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363 9427 (2004) 2105-2115
117. Gale C.R., Martyn C.N., and Cooper C. Cognitive impairment and mortality in a cohort of elderly people. BMJ 312 7031 (1996) 608-611
118. Goodwin J.S., Goodwin J.M., and Garry P.J. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 249 21 (1983) 2917-2921
119. La Rue A., Koehler K.M., Wayne S.J., et al. Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment. Am J Clin Nutr 65 1 (1997) 20-29
120. Morris M.C., Beckett L.A., Scherr P.A., et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 12 3 (1998) 121-126
121. Perrig W.J., Perrig P., and Stahelin H.B. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 45 6 (1997) 718-724
122. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336 17 (1997) 1216-1222
123. Miller III E.R., Pastor-Barriuso R., Dalal D., et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 1 (2005) 37-46
124. Aisen P.S., and Davis K.L. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 151 8 (1994) 1105-1113
125. McGeer P.L., and Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42 2 (1992) 447-449
126. Andersen K., Launer L.J., Ott A., et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45 8 (1995) 1441-1445
127. Breitner J.C., Welsh K.A., Helms M.J., et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16 4 (1995) 523-530
128. Breitner J.C., Gau B.A., Welsh K.A., et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44 2 (1994) 227-232
129. Canadian Study of Health and Aging Working Group. Risk factors for Alzheimer's disease in Canada. Neurology 44 11 (1994) 2073-2080
130. Stewart W.F., Kawas C., Corrada M., et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 3 (1997) 626-632
131. Aisen P.S., Davis K.L., Berg J.D., et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54 3 (2000) 588-593
132. Rogers J., Kirby L.C., Hempelman S.R., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43 8 (1993) 1609-1611
133. Scharf S., Mander A., Ugoni A., et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53 1 (1999) 197-201
134. Aisen P.S., Schafer K.A., Grundman M., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 21 (2003) 2819-2826
135. Ho L., Pieroni C., Winger D., et al. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res 57 3 (1999) 295-303
136. Pasinetti G.M., and Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87 2 (1998) 319-324
137. Sainati SM, Ingram DM, Talwalker S, et al. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. Paper presented at the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm (Sweden), April 5-8, 2000.
138. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 8 (2001) 954-959
139. Topol E.J. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 351 17 (2004) 1707-1709
140. Launer L. Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. Drugs 63 8 (2003) 731-739
141. in t' Veld B.A., Ruitenberg A., Hofman A., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345 21 (2001) 1515-1521
142. Weggen S., Eriksen J.L., Das P., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 6860 (2001) 212-216
143. Weggen S., Eriksen J.L., Sagi S.A., et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 278 34 (2003) 31831-31837
144. Henderson V.W., Paganini-Hill A., Emanuel C.K., et al. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 51 9 (1994) 896-900
145. Kawas C., Resnick S., Morrison A., et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology 48 6 (1997) 1517-1521
146. Paganini-Hill A., and Henderson V.W. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 140 3 (1994) 256-261
147. Paganini-Hill A., and Henderson V.W. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 156 19 (1996) 2213-2217
148. Shumaker S.A., Legault C., Rapp S.R., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 20 (2003) 2651-2662
149. Rapp S.R., Espeland M.A., Shumaker S.A., et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 20 (2003) 2663-2672
150. Shumaker S.A., Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 24 (2004) 2947-2958
151. Espeland M.A., Rapp S.R., Shumaker S.A., et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 24 (2004) 2959-2968
152. Sano M. Moving from treatment to prevention in Alzheimer's disease with vitamin E and estrogen. Psychiatric Times 16 (1999) 1-4
153. McBee W.L., Dailey M.E., Dugan E., et al. Hormone replacement therapy and other potential treatments for dementias. Endocrinol Metab Clin North Am 26 2 (1997) 329-345
154. Mulnard R.A., Cotman C.W., Kawas C., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 283 8 (2000) 1007-1015
155. Henderson V.W., Paganini-Hill A., Miller B.L., et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 54 2 (2000) 295-301
156. Roberts R.O., Cha R.H., Knopman D.S., et al. Postmenopausal estrogen therapy and Alzheimer disease: overall negative findings. Alzheimer Dis Assoc Disord 20 3 (2006) 141-146
157. Masters C.L., and Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 129 Pt 11 (2006) 2823-2839
158. Selkoe D.J. The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. Neurol Clin 18 4 (2000) 903-922
159. Hussain I., Powell D., Howlett D.R., et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14 6 (1999) 419-427
160. Sinha S., Anderson J.P., Barbour R., et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402 6761 (1999) 537-540
161. Vassar R., Bennett B.D., Babu-Khan S., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 5440 (1999) 735-741
162. Yan R., Bienkowski M.J., Shuck M.E., et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402 6761 (1999) 533-537
163. Garino C., Tomita T., Pietrancosta N., et al. Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays. J Med Chem 49 14 (2006) 4275-4285
164. Siemers E.R., Quinn J.F., Kaye J., et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66 4 (2006) 602-604
165. Dovey H.F., John V., Anderson J.P., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76 1 (2001) 173-181
166. Eriksen J.L., Sagi S.A., Smith T.E., et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112 3 (2003) 440-449
167. Anderson J.J., Holtz G., Baskin P.P., et al. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 69 4 (2005) 689-698
168. Black S., Wilcock G., Haworth J., et al. Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study. Neurology 66 5 Suppl 2 (2006) A347
169. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 6740 (1999) 173-177
170. Orgogozo J.M., Gilman S., Dartigues J.F., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 1 (2003) 46-54
171. Gilman S., Koller M., Black R.S., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 9 (2005) 1553-1562
172. Masliah E., Hansen L., Adame A., et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 1 (2005) 129-131
173. Fox N.C., Black R.S., Gilman S., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 9 (2005) 1563-1572
174. Dodel R., Hampel H., Depboylu C., et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 52 2 (2002) 253-256
175. Dodel R.C., Du Y., Depboylu C., et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 10 (2004) 1472-1474
176. Adamiak B., Monthe C., Bender H., et al. Intravenous immunoglobulin (IVIg) maintains cognition over 18 months in patients with Alzheimer's disease (AD). Alzheimers Dement 2 3 (2006) S62-S63
177. Chung J.A., and Cummings J.L. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurol Clin 18 4 (2000) 829-846
178. Henderson D.C., Cagliero E., Copeland P.M., et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62 1 (2005) 19-28
179. Ballard C., Bannister C., Solis M., et al. The prevalence, associations and symptoms of depression amongst dementia sufferers. J Affect Disord 36 3-4 (1996) 135-144
180. Borson S., and Raskind M.A. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology 48 5 Suppl 6 (1997) S17-S24
181. Devanand D.P., Jacobs D.M., Tang M.X., et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 54 3 (1997) 257-263
182. Mega M.S., Cummings J.L., Fiorello T., et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology 46 1 (1996) 130-135
183. Reisberg B., Borenstein J., Salob S.P., et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 48 Suppl (1987) 9-15
184. Cohen-Mansfield J., and Deutsch L.H. Agitation: subtypes and their mechanisms. Semin Clin Neuropsychiatry 1 4 (1996) 325-339
185. Cummings J.L., Mega M., Gray K., et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 12 (1994) 2308-2314
186. Kaufer D.I., Cummings J.L., Ketchel P., et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12 2 (2000) 233-239
187. Devanand D.P., Sano M., Tang M.X., et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 53 2 (1996) 175-182
188. Cooper J.K., Mungas D., Verma M., et al. Psychotic symptoms in Alzheimer's disease. Int J Geriatr Psychiatry 6 10 (1991) 721-726
189. Rubin E.H., Drevets W.C., and Burke W.J. The nature of psychotic symptoms in senile dementia of the Alzheimer type. J Geriatr Psychiatry Neurol 1 1 (1988) 16-20
190. Stern Y., Albert M., Brandt J., et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology 44 12 (1994) 2300-2307
191. Katz I.R., Jeste D.V., Mintzer J.E., et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 60 2 (1999) 107-115
192. McManus D.Q., Arvanitis L.A., and Kowalcyk B.B. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry 60 5 (1999) 292-298
193. Street J.S., Clark W.S., Gannon K.S., et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 57 10 (2000) 968-976
194. Schneider L.S., Tariot P.N., Dagerman K.S., et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 15 (2006) 1525-1538
195. Schneider L.S., Dagerman K., and Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14 3 (2006) 191-210
196. McAllister T.W. Apathy. Semin Clin Neuropsychiatry 5 4 (2000) 275-282
197. Deutsch L.H., Bylsma F.W., Rovner B.W., et al. Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry 148 9 (1991) 1159-1163
198. Sultzer D.L., Gray K.F., Gunay I., et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 5 1 (1997) 60-69
199. Tariot P.N., Erb R., Podgorski C.A., et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 155 1 (1998) 54-61
200. Porsteinsson A.P., Tariot P.N., Erb R., et al. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 5 4 (1997) 344-351